PMID- 23996476
OWN - NLM
STAT- MEDLINE
DCOM- 20140325
LR  - 20211021
IS  - 1534-6277 (Electronic)
IS  - 1534-6277 (Linking)
VI  - 14
IP  - 3
DP  - 2013 Sep
TI  - Dermatologic adverse events to targeted therapies in lower GI cancers: clinical 
      presentation and management.
PG  - 389-404
LID - 10.1007/s11864-013-0254-4 [doi]
AB  - Rapid advances in drug discovery and the regulatory approval of a number of novel 
      anticancer agents during the past decade pose unique challenges to the oncology 
      community. While the benefits of such therapies receive most attention, adverse 
      events (AEs), especially those pertaining to subspecialties (e.g., dermatology), 
      often are underemphasized. To ensure best clinical outcomes, it would be 
      important to bridge the gap between approval of a new drug and devising effective 
      management strategies for the AEs. With the incorporation of targeted therapies 
      to the treatment paradigm of gastrointestinal malignancies, there has been a 
      significant rise in dermatologic AEs among those treated. In addition to 
      significantly affecting patients' quality of life, these AEs represent a growing 
      problem and are relatively unfamiliar to many oncologists. The issue is further 
      complicated by the lack of evidence-based management guidelines for such AEs in 
      the oncology setting, the "generalizing" of terminology (e.g., rash) for some 
      AEs, as well as an insufficient number of oncodermatologists for assistance with 
      their management. It is important for the oncologist to gain familiarity with the 
      most common, manageable and predictable AEs. Their identification is usually 
      based on medical history, clinical features, and full-body skin examination 
      (FBSE) and at times by obtaining a skin biopsy to aid in diagnosis. Although 
      efforts are underway, presently, there is a paucity of biomarkers (e.g., 
      serologic, genetic) to predict dermatologic AEs. Management often requires a 
      multifaceted approach and includes topical, systemic, surgical, and physical 
      (e.g., cryotherapy) modalities of treatment. Unfortunately, very few clinical 
      trials have focused on this aspect of supportive care; therefore, most data on 
      management derives from anecdotal data. Patients should be encouraged to actively 
      report skin problems, while oncologists should play a vital role in addressing 
      these AEs in their patients. Lastly, further research at the molecular and 
      cellular level may assist in the elucidation of the mechanisms underlying these 
      AEs and their clinical correlates, paving way for the design of effective 
      therapies in this subset of patients.
FAU - Belum, Viswanath Reddy
AU  - Belum VR
AD  - Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer 
      Center, Rockefeller Outpatient Pavilion, Suite 228, 160 E 53rd St., New York, NY, 
      10022, USA.
FAU - Cercek, Andrea
AU  - Cercek A
FAU - Sanz-Motilva, Virginia
AU  - Sanz-Motilva V
FAU - Lacouture, Mario E
AU  - Lacouture ME
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Treat Options Oncol
JT  - Current treatment options in oncology
JID - 100900946
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 15C2VL427D (aflibercept)
RN  - 24T2A1DOYB (regorafenib)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 6A901E312A (Panitumumab)
RN  - EC 2.7.10.1 (Receptors, Vascular Endothelial Growth Factor)
RN  - PQX0D8J21J (Cetuximab)
SB  - IM
MH  - Antibodies, Monoclonal/adverse effects
MH  - Antibodies, Monoclonal, Humanized/adverse effects
MH  - Antineoplastic Agents/administration & dosage/*adverse effects
MH  - Bevacizumab
MH  - Cetuximab
MH  - Clinical Trials as Topic
MH  - Drug-Related Side Effects and Adverse Reactions/classification/*pathology
MH  - Gastrointestinal Neoplasms/*drug therapy/pathology
MH  - Humans
MH  - Molecular Targeted Therapy
MH  - Panitumumab
MH  - Phenylurea Compounds/adverse effects
MH  - Pyridines/adverse effects
MH  - Receptors, Vascular Endothelial Growth Factor/adverse effects
MH  - Recombinant Fusion Proteins/adverse effects
MH  - Skin/*drug effects/pathology
EDAT- 2013/09/03 06:00
MHDA- 2014/03/26 06:00
CRDT- 2013/09/03 06:00
PHST- 2013/09/03 06:00 [entrez]
PHST- 2013/09/03 06:00 [pubmed]
PHST- 2014/03/26 06:00 [medline]
AID - 10.1007/s11864-013-0254-4 [doi]
PST - ppublish
SO  - Curr Treat Options Oncol. 2013 Sep;14(3):389-404. doi: 10.1007/s11864-013-0254-4.